Cary C. Cotton

Cary C. Cotton

Auto-generated profile, based on publicly available information

Cary C. Cotton

University of North Carolina School of Medicine, Chapel Hill, NC

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
SESwathi Eluri
Swathi Eluri
TRThomas M. Runge
Thomas M. Runge
CCCary C. Cotton
Cary C. Cotton
CBCaitlin M. Burk
Caitlin M. Burk
WWW. Asher Wolf
W. Asher Wolf
EDEvan S. Dellon
Evan S. Dellon

1 June 2015 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
CCCary C. Cotton
Cary C. Cotton
WWW. Asher Wolf
W. Asher Wolf
SPSarina Pasricha
Sarina Pasricha
NLNan Li
Nan Li
RMRyan D. Madanick
Ryan D. Madanick
NSNicholas J. Shaheen
Nicholas J. Shaheen

18 May 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
SBShweta Bhatia
Shweta Bhatia
CCCary C. Cotton
Cary C. Cotton
EKErin Kim
Erin Kim
HAHannah Angle
Hannah Angle
AWAriel E. Watts
Ariel E. Watts
NSNicholas J. Shaheen
Nicholas J. Shaheen

9 December 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
CRCraig C. Reed
Craig C. Reed
SAStefani Aleman
Stefani Aleman
AWAlexandra A. Weir
Alexandra A. Weir
SLSean S. LaFata
Sean S. LaFata
TGTimothy S. Gee
Timothy S. Gee
EDEvan S. Dellon
Evan S. Dellon
INTRODUCTION: Assessment of eosinophilic esophagitis (EoE) endoscopic findings is critical in determining disease activity. However, response thresholds for the EoE Endoscopy Reference Score (EREFS) are not definitively established. We assessed EREFS response thresholds in patients with EoE treated with topical corticosteroids. METHODS: We conducted a retrospective cohort study of newly diagnosed patients with EoE treated with topical corticosteroid who had a follow-up endoscopy with biopsy and EREFS assessed pretreatment/post-treatment. We explored endoscopic response thresholds. Patients with and without endoscopic response were compared and predictors of response were determined. Histologic and global symptom responses were determined and residual endoscopic findings calculated. RESULTS: Of 333 patients, 219 (68%), 206 (62%), 142 (43%), 70 (21%), 139 (42%), and 142 (43%) met response thresholds for EREFS ≤2, EREFS ≤2 with no components >1 nor worsening of any component, EREFS ≤1, EREFS = 0, inflammatory subscore = 0, and fibrostenotic subscore = 0, respectively. On multivariate analysis, lower body mass index (adjusted odds ratio [aOR]: 0.90; 95% confidence interval [CI]: 0.85–0.95), heartburn (aOR: 2.74; 95% CI: 1.37–5.48), and lower total baseline EREFS (aOR: 0.57; 95% CI: 0.29–0.71) independently predicted EREFS ≤2. After treatment, 74% with EREFS≤2 vs 23% with EREFS>2 ( P < 0.001) had histologic response at <15 eos/hpf. Endoscopic responders more frequently endorsed a global symptom response (89% vs 56%; P < 0.001) and had minimal residual endoscopic findings. Outcomes stratified for adults and children were comparable with the entire cohort. DISCUSSION: Post-treatment EREFS ≤2 was consistent with symptom and histologic response for the entire cohort. These data support EREFS ≤2 as a robust threshold to define endoscopic response.

27 September 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
CCCary C. Cotton
Cary C. Cotton
MBMousumi Biswas
Mousumi Biswas
EDEvan S. Dellon
Evan S. Dellon
INTRODUCTION: We aimed to estimate health state utility in eosinophilic esophagitis (EoE) by histologic activity and assess association with disease parameters. METHODS: In this cross-sectional study, we measured health state utility by time trade-off and assessed symptoms with the EoE Symptom Activity Index. RESULTS: In 51 adults with EoE, the mean utility was 0.91 (95% CI 0.86, 0.95). Utility was numerically worse in patients with dilation or a smaller stricture diameter. With each ten-point improvement in EoE Symptom Activity Index, utility increased by 0.03 (95% CI 0.01, 0.05). DISCUSSION: EoE is associated with reduced health state utility, with symptoms most strongly predicting valuation.

15 April 2022 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
CCCary C. Cotton
Cary C. Cotton
NSNicholas J. Shaheen
Nicholas J. Shaheen
ATAaron P. Thrift
Aaron P. Thrift
INTRODUCTION: Endoscopic eradication therapy with radiofrequency ablation (RFA) and endoscopic mucosal resection is a safe and effective treatment for Barrett's esophagus. Although the outcomes of surveillance endoscopy after successful endoscopic eradication therapy have been described, no previous studies have modeled the natural history or the effect of surveillance endoscopy after successful ablation to prevent progression to invasive esophageal adenocarcinoma. METHODS: The US RFA Registry is a multicenter registry consisting of patients treated with RFA for Barrett's esophagus at 148 institutions (113 community-based and 35 academic-affiliated). The authors fit models to impute the natural history of recurrence and neoplastic progression after any recurrence or retreatment. Natural history estimates of invasive adenocarcinoma after ablation therapy were compared with as-treated estimates at 5 years to derive the preventive risk difference for surveillance. RESULTS: Natural history estimates for the postablation progression of high-grade dysplasia (HGD) or intramucosal adenocarcinoma to invasive adenocarcinoma after treatment were 6.3% at 5 years compared with 1.3% for low-grade dysplasia (LGD). The natural history model found a much higher preventative risk difference for surveillance for HGD/intramucosal adenocarcinoma (−4.8%), compared with LGD (−1.1%). The numbers needed to surveil at 5 years were 21 and 90 for these groups, respectively, to prevent one case of invasive esophageal adenocarcinoma, making surveillance after successful ablation of baseline HGD more than 4 times as effective at preventing invasive cancer than after successful ablation of baseline LGD. DISCUSSION: Endoscopic surveillance after successful ablation of baseline HGD or intramucosal cancer is much more effective than surveillance after successful treatment of baseline LGD in averting invasive adenocarcinoma. Although the modest benefits of surveillance for treated LGD may be greater than the risks for patients at average risk for adverse effects of endoscopy, clinicians should concentrate on retaining patients with baseline HGD or cancer in endoscopic surveillance programs.